Back to Search Start Over

Estrogen receptor alpha gene variants are associated with Alzheimer's disease

Authors :
Boada, Mercé
Antunez, Carmen
López-Arrieta, Jesús
Caruz, Antonio
Moreno-Rey, Concha
Ramírez-Lorca, Reposo
Morón, Francisco Jesús
Hernández, Isabel
Mauleón, Ana
Rosende-Roca, Maiteé
Martínez-Lage, Pablo
Marín, Juan
Tárraga, Lluis
Alegret, Montserrat
Pedrajas, José Rafael
Urda, Nuria
Royo, José Luis
Saez, María Eugenia
Gayán, Javier
González-Pérez, Antonio
Source :
Neurobiology of Aging. Jan2012, Vol. 33 Issue 1, p198.e15-198.e24. 0p.
Publication Year :
2012

Abstract

Abstract: The present research is aimed at assessing the role of 3 estrogen receptor alpha (ESR1) gene variants in late onset Alzheimer''s disease (AD) susceptibility. One thousand one hundred thirteen unrelated late onset sporadic AD patients, 1109 healthy controls and 121 neurologically healthy elderly controls were used to carry out case-control genetic association studies with ESR1 rs3844508, rs2234693, and ESR1 noncoding deletion 1 (ESR1-NCD1) polymorphisms. Thirty-five healthy male samples were used for molecular analyses. The rs2234693 polymorphism is associated with AD in our population (odds ratio [OR], 1.29; p = 0.008). The rs3844508 marker confers protection against AD in males (OR, 0.57; p = 0.001) and the deletion ESR1-NCD1 is a risk factor for AD in women (OR, 1.67; p < 0.001). Molecular analyses on ESR1-NCD1 indicate that this deletion confers a higher response to estradiol activity on ESR1 receptor and it is also associated with differential expression of ESR1 isoforms. Our results support the involvement of ESR1 gene in AD and point to the existence of sexual dimorphism for ESR1 markers. In addition, carriers of ESR1-NCD1 deletion could overrespond to estradiol action. [Copyright &y& Elsevier]

Details

Language :
English
ISSN :
01974580
Volume :
33
Issue :
1
Database :
Academic Search Index
Journal :
Neurobiology of Aging
Publication Type :
Academic Journal
Accession number :
67321031
Full Text :
https://doi.org/10.1016/j.neurobiolaging.2010.06.016